SecBot SecBot
Biotech Drug Report Generated Nov 15, 2026

SimpleScreen CRC

FRNM·Freenome, Inc.
BULLISH
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market. The FDA approved SimpleScreen CRC on July 27, 2026. Abbott commercially launched the test in the United States in late September 2026.
Why 4/10
SimpleScreen CRC is already FDA-approved and commercially launched with no upcoming PDUFA or pivotal-readout catalyst in the next ~12 months. The next potential regulatory catalyst would be an FDA submission for the next-generation version, for which no filing date has been announced. As an approved, marketed product, the defining binary has passed, capping the impact score at 5, and the lack of a near-term dated catalyst holds it at 4.
Actionable Insight BULLISH

SimpleScreen CRC's defining binary (FDA approval) has passed, removing the high-impact binary catalyst. The stock now trades on the commercial execution story via Abbott and on pipeline expansion (lung test). Watch Q4 2026 revenue (due early 2027) for evidence of recurring test-sale volume versus one-time milestones; the next-gen validation data and a potential FDA filing for the updated version are the next potential catalysts to watch for.

Price Chart

Loading chart...

Executive Summary

Freenome's SimpleScreen CRC is a blood-based colorectal cancer screening test that won FDA approval in July 2026 and was commercially launched in the US by partner Abbott in late September 2026. Q32026 revenue of $183.5 million (versus $1 million a year earlier) was driven largely by milestone payments from Abbott, and the company beat EPS estimates ($0.57 actual vs $0.41 consensus). The test competes with Guardant Health's Shield blood test (approved 2024) and stool-based tests (Cologuard Plus, now also owned by Abbott). The stock trades at $10.41, well below the $18 mean analyst target, though the approved status and partnership with Abbott provide a commercial floor while a next-gen version and newly launched SimpleScreen Lung represent pipeline upside.

How It Works

SimpleScreen CRC is a blood test that screens for colorectal cancer by detecting multiple biological signals (DNA, RNA, proteins) shed by tumors into the bloodstream. A doctor draws blood in the office; results come back in about two weeks. A positive result requires a follow-up colonoscopy.

Trial Status

SimpleScreen CRC completed a pivotal clinical validation study whose top-line readout on July 9, 2026 showed it met all primary and secondary endpoints. The test achieved approximately 81% sensitivity for colorectal cancer detection in average-risk adults 45+. An updated version of the test presented at the American College of Gastroenterology (ACG) meeting in October 2026 showed improved detection of advanced precancerous lesions (18.2% sensitivity, up from the original version).

The Two-Sided Case

▲ Bull Case7
FDA-approved and commercially launched: the test is the second blood-based CRC screening test to reach the US market, and Abbott handles all US commercialization, giving Freenome a powerful distribution partner.
Q32026 results show the business model working: revenue jumped to $183.5 million (from $1 million) and EPS of $0.57 beat the $0.41 consensus, driven by milestone revenue from Abbott.
Analyst consensus is overwhelmingly bullish: 6 Strong Buy, 4 Buy, and only 1 Hold, with a mean price target of $18 (72.9% implied upside from $10.41).
Institutional accumulation is strong: ARK Invest, BlackRock, FMR, UBS, Alphabet, and others all took new positions in Q32026, reflecting confidence in the commercial opportunity.
Targeting a large untapped market: approximately 50 million Americans who are eligible but unscreened for colorectal cancer, where a simple blood test could drive higher screening adherence.
Pipeline expansion: Freenome launched SimpleScreen Lung in October 2026 and received FDA Breakthrough Device Designation for it, offering a multi-cancer screening story.
The company ended Q32026 with approximately $410 million in cash, providing a long runway.
▼ Bear Case5
Competition is intensifying: Guardant Health's Shield blood test (approved 2024) has first-mover advantage and expanding insurance coverage. Abbott's ownership of both Cologuard Plus (stool) and SimpleScreen CRC (blood) may cannibalize one or the other.
Clinical performance is mid-tier: SimpleScreen CRC's ~81% sensitivity for colorectal cancer lags behind stool-based tests like Cologuard (over 90%) and colonoscopy (the gold standard). The test is positioned as a second-line option for those unwilling to do stool tests or colonoscopy, not as a replacement.
Stock dropped 11% in October 2026 after the next-gen data at ACG showed 'clinically meaningful' improvement but apparently disappointed expectations for bigger gains.
The revenue spike in Q3 was largely milestone-driven, not recurring test sales. Sustained recurring revenue from commercial test volumes remains unproven this early in the launch.
The stock trades well below its 52-week high of $17.50 (now $10.41), and the company faces dilution risk from its recent $310 million IPO and any future capital raises to fund pipeline development.

Upcoming Catalysts

  • Commercial ramp and recurring test-volume revenue updates from Freenome (next quarterly earnings)
  • Potential FDA submission timing for the next-generation version of SimpleScreen CRC with improved precancerous-lesion detection
  • SimpleScreen Lung Breakthrough Device designation progress and potential FDA approval pathway
  • Insurance coverage decisions and Medicare reimbursement updates for SimpleScreen CRC

Source Filing

The SEC filing that triggered this drug report:

Freenome, Inc. SEC filing FRNM ·Accession 0002017526-26-000019

Sources · 5

Hover a chip for the title
1 fiercebiotech.com2 medpagetoday.com3 sec.gov4 ad-hoc-news.de5 markets.businessinsider.com